| Chapter title |
Biomarker Immunoassays in the Diagnosis of Preeclampsia: Calculating the sFlt1/PlGF Ratio Using the Cobas®e 411 Analyser
|
|---|---|
| Chapter number | 2 |
| Book title |
Preeclampsia
|
| Published in |
Methods in molecular biology, January 2018
|
| DOI | 10.1007/978-1-4939-7498-6_2 |
| Pubmed ID | |
| Book ISBNs |
978-1-4939-7497-9, 978-1-4939-7498-6
|
| Authors |
Carin Black, Fabricio da Silva Costa |
| Abstract |
Preeclampsia is a relatively common pregnancy-related condition associated with serious maternal and fetal morbidity and mortality. It is now well established that anti-angiogenic sFlt1 is upregulated in preeclampsia and binds PlGF and VEGF, causing an imbalance in angiogenic factors with subsequent endothelial injury and dysfunction. Measurement of placental growth factor (PlGF) and the sFlt1/PlGF ratio have both been validated in other countries for screening and diagnosis of preeclampsia and the differentiation of preeclampsia from other hypertensive disorders of pregnancy. There are several automated, commercially available immunoassays capable of measuring PlGF and the sFlt1/PlGF ratio for preeclampsia diagnosis. Here we outline the methodology for using the Roche Cobas ® e 411 immunoassay platform to determine the sFlt1/PlGF ratio. |
Mendeley readers
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 35 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 4 | 11% |
| Researcher | 4 | 11% |
| Student > Master | 4 | 11% |
| Student > Ph. D. Student | 3 | 9% |
| Student > Doctoral Student | 1 | 3% |
| Other | 3 | 9% |
| Unknown | 16 | 46% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 9 | 26% |
| Biochemistry, Genetics and Molecular Biology | 3 | 9% |
| Nursing and Health Professions | 2 | 6% |
| Immunology and Microbiology | 1 | 3% |
| Agricultural and Biological Sciences | 1 | 3% |
| Other | 0 | 0% |
| Unknown | 19 | 54% |